These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23841505)

  • 1. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
    Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
    Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus in diffuse large B-cell lymphomas.
    Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
    Future Oncol; 2015; 11(3):373-83. PubMed ID: 25675120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
    Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
    Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
    Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
    Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
    Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
    Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
    Xu CX; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    PLoS One; 2011; 6(6):e20899. PubMed ID: 21695126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á
    Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
    Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
    Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway.
    Li X; Wang X; Zhang M; Li A; Sun Z; Yu Q
    Cell Biochem Biophys; 2014 Nov; 70(2):1357-62. PubMed ID: 24902540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
    Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marine sponge-derived alkaloid inhibits the PI3K/AKT/mTOR signaling pathway against diffuse large B-cell lymphoma.
    Liu J; Chang YT; Kou YY; Zhang PP; Dong QL; Guo RY; Liu LY; Lin HW; Yang F
    Med Oncol; 2024 Jul; 41(9):212. PubMed ID: 39073639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
    Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
    Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
    Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
    Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.